Codexis (CDXS) Stock
Engineered enzyme company for pharmaceutical and industrial markets. Here's the price, business snapshot, and what's worth knowing about Codexis in October 2026.
Codexis, Inc. (CDXS) is a protein engineering company that designs and commercialises engineered enzymes for pharmaceutical development, biocatalysis and industrial applications. Investors should know Codexis operates a platform-led model: its proprietary CodeEvolver® technology seeks to speed enzyme discovery and optimisation, which the company monetises via collaborations, licensing and product sales. Revenue drivers include partnerships with large drugmakers, royalties from licensed programmes and productised enzyme offerings. As a small-cap biotech (market cap ~ $249M) the stock can be sensitive to partnership updates, development milestones and quarterly results. Strengths include strong scientific IP and established commercial deals, but risks include dependence on a limited number of partners, competitive enzyme technologies, and the general volatility of the biotech sector. This summary is educational and not personal advice; potential investors should assess suitability, consider diversification, and be aware that past performance is not a reliable guide to future returns.
Codexis (CDXS) Stock Forecast
Analyst price target, next 12 months
$7.18
+428.1% vs today's $1.36
Price range over the last 12 months
Close to its 12-month low
Analysts covering Codexis have a consensus 12-month target of $7.18, above the current price of $1.36.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 2 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Codexis Inc.'s stock with a target price of $7.18, indicating strong growth potential.
Financial Health
Codexis is earning moderate revenue and cash flow, but its profitability is fairly stable.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Platform-driven Growth
CodeEvolver® aims to accelerate enzyme discovery, supporting collaborations and licences that can drive revenue — though commercial uptake can take time.
Partner-led Commercial Model
Codexis often monetises through partnerships and royalties with large pharma and industrial customers, which can provide scalable opportunities but also concentration risk.
Small-cap Volatility Risk
Market moves can be pronounced for small biotechnology firms; investors should consider suitability and diversification before taking a position.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
